
Loneliness May Drive Depression, Poor Physical Health
Frequent loneliness was associated with a higher probability of depression and an increased number of poor mental and physical health days per month than never feeling lonely in a new survey-based study. Additionally, significant disparities were observed across sex, race/ethnicity, and age groups.
METHODOLOGY:
Investigators assessed data for more than 47,000 US adults (62% women; 73% White individuals) obtained from the Behavioral Risk Factor Surveillance System between 2016 and 2023.
They analyzed the potential association between loneliness and key health outcomes, including a diagnosis of depression and the self-reported number of days in the past month with poor mental or physical health.
Participants self-reported the frequency of feeling lonely, which was categorized as always, usually, sometimes, rarely, and never.
TAKEAWAY:
Participants who reported always, usually, sometimes, and rarely feeling lonely had a significantly higher probability of depression (50%, 48%, 31%, and 16%, respectively; P < .001 for all) than those who reported never feeling lonely (10%). Those who reported always feeling lonely had 10.9 more poor mental health days and 5 more poor physical health days in a month on average than those who were never lonely (P < .001 for all).
Women had a higher probability of depression than men across all loneliness levels (P < .001). There was also a significantly greater number of poor mental health days in women vs men who felt lonely sometimes (mean difference, 0.8 days; P = .002) and rarely (mean difference, 0.7 days; P = .003).
Black and Hispanic individuals reporting loneliness had significantly lower probabilities of depression than their White peers (P < .05 for both). Among participants who felt always lonely, Black individuals reported fewer poor mental health days (mean difference, -3.8 days; P = .005) and fewer poor physical health days (mean difference, -3.6 days; P = .01) in a month than White individuals.
Middle-aged (45-64 years) and older adults (> 64 years) with loneliness reported a greater number of poor physical health days in a month than younger adults (18-44 years) across all loneliness categories (P < .001 for all). However, older adults had a significantly lower risk for depression than younger adults across most loneliness levels.
IN PRACTICE:
'Addressing loneliness may not only improve individual well-being but also reduce societal healthcare burdens,' the investigators wrote.
'The findings of this study carry urgent policy and practice implications. Given the pervasiveness and potency of loneliness, it should be prioritized alongside traditional risk factors in public health planning,' they added.
SOURCE:
The study was led by Oluwasegun Akinyemi, MD, PhD, Howard University College of Medicine, Washington, DC. It was published online on July 9 in PLOS One.
LIMITATIONS:
Key limitations included the study's cross-sectional design, residual confounding by unmeasured factors, and its reliance on self-reported measures. Additionally, telephone-based survey methods may have underrepresented the most socially isolated individuals.
DISCLOSURES:
The study was funded in part by the National Institute on Minority Health and Health Disparities. The investigators reported having no relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed company, reported its Phase 2b trial of inidascamine for cognitive impairment linked to schizophrenia missed its primary endpoint. Warning! GuruFocus has detected 6 Warning Signs with ATAI. The oral compound, engineered to modulate multiple neurotransmitter pathways for pro?cognitive effects, failed to outperform placebo on key cognitive measures. Recognify said the results fell short of statistical significance. Atai's CEO acknowledged the setback but highlighted inidascamine's potential in CIAS and other indications. He added that Atai will redirect its efforts toward its wholly?owned psychedelic programs focused on affective disorders. Investors have been closely watching Atai's broader pipeline, which includes compounds targeting depression, PTSD and Alzheimer's disease. This latest trial disappointment adds to a string of mid?stage readouts that have tested market sentiment around biotech firms pivoting to next?generation neuroscience therapies. Despite today's drop, Atai's management reiterated its commitment to advancing its lead psychedelic candidates through upcoming Phase 1 and Phase 2 trials. Based on the one year price targets offered by 6 analysts, the average target price for ATAI Life Sciences NV is $9.83 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies a upside of +175.44% from the current price of $3.57. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Parents call on FDA for path forward after Duchenne's gene therapy pause
The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient receiving treatment for muscular dystrophy. Alison and William Small are urging the agency to restore access to the drug, the only FDA-approved treatment for Duchenne's muscular dystrophy. Speaking to 'Morning in America,' the Smalls call for transparency and a clear path forward from federal regulators. They say families affected by Duchenne's deserve to understand the risks and that many believe the treatment is worth fighting for. Solve the daily Crossword


Forbes
30 minutes ago
- Forbes
OpenEvidence's Meteoric Rise Is Huge For Doctors
Medical research and science has never been easier to access. OpenEvidence has raised hundreds of millions of dollars. In its most recent funding round, it raised a $210 million Series B from prominent investors such as Google Ventures and Kleiner Perkins, bringing the company's valuation to nearly $3.5 billion. The company's goal is straightforward and incredibly ambitious: to collate the entire corpus of medical knowledge and research developments in a way that is easily accessible to physicians and thereby, improve health outcomes. The service is aiming to provide a similar 'touch and feel' as other generative AI services such as Chat GPT or Google's Gemini—except, its target audience is primarily doctors. Medical science is a rapidly evolving field with a perpetually expanding sea of knowledge, especially as research and development across the fields of disease, therapeutics and human sciences continue to grow. In fact, as Sequoia Capital notes, 'a new PubMed article [which is often the flagship resource for peer-reviewed science studies]The value of this type of technology is increasingly being recognized. The latest models for OpenAI's ChatGPT (GPT 4.1 and o3) have displayed incredible efficacy in taking command of medical knowledge; in May, the company published its work with HealthBench, proposing a rubric for model performance in healthcare and also indicating that GPT's latest models performed at par or even better than standard physician evaluations. Even Google's Gemini family of models has made significant progress in this space; its MedLM suite, for example, is a highly tuned model that can aid the entire healthcare workflow, ranging from answering medical questions to deciphering unstructured health data. Why is all of this important? There are a few different reasons. First and foremost, this technology is aiming to democratize medical knowledge in a way that is easy to access. Furthermore, it comes at a time when the healthcare system, and its respective workforce, is facing unprecedented headwinds. Studies have repeatedly indicated that physician burnout and attrition are incredibly concerning problems for health systems and organizations of all sizes; physicians simply do not have the bandwidth to fulfill all of their patient care duties in addition to the increasingly prevalent administrative, compliance and regulatory burdens placed on them. This also means that there is less time for professional development and continuing education. These technologies can serve as a major advantage to the physician workflow as they provide an opportunity to easily query, fact-check and understand the latest science that is involved with a condition. Carry this even further with tools such as OpenEvidence DeepConsult, which gives physicians access to PhD-level AI agents that can conduct medical research, or Gemini's foundation models that can rapidly decipher medical images, or even AI scribing technology that can rapidly generate patient-physician encounter notes, and soon, hours can be saved from a physician's daily workflow. This translates not only to millions of dollars saved annually in system costs, but also to more time available to spend with patients, improved access to care, and ultimately, increased efficacy and quality of care provided.